CLAIMS

1. Use of a combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof and an interferon (IFN) agent or a functional fragment thereof, for preparing a medicament for use for treating a HBV infection.

2. The use according to claim 1, wherein the TNFRSF agonist or a functional fragment thereof is selected from the group consisting of a lymphotoxin alpha 3 receptor agonist, a lymphotoxin beta receptor agonist, a herpesvirus entry mediator agonist, a tumor necrosis factor-like receptor weak inducer of apoptosis agonist, a cluster of differentiation factor 40 agonist, a CD27 agonist, a CD30 agonist, a 4-1BB agonist, a receptor activator of nuclear factor κB agonist, a Troy agonist, and a OX40 receptor agonist, or functional fragments thereof.

3. The use according to claim 1 or 2, wherein the TNFRSF agonist or a functional fragment thereof is selected from the group consisting of CD40L, LTα3, LIGHT and TWEAK, or functional fragments thereof.

4. The use according to any one of claims 1 to 3, wherein the TNFRSF agonist or a functional fragment thereof is selected from the group consisting of CD40L, LIGHT and TWEAK, or functional fragments thereof.

5. The use according to any one of claims 1 to 4, wherein the TNFRSF agonist or a functional fragment thereof is a CD40 agonist or a functional fragment thereof selected from the group consisting of a CD40 ligand (CD40L) or a functional fragment thereof, an agonistic anti-CD40 antibody, a functional fragment thereof or antigen-binding fragment thereof, and a fusion protein comprising a CD40 ligand or a functional fragment thereof.

6. The use according to claim 5, wherein the CD40L is hexameric CD40L or trimeric CD40L.

7. The use according to any one of claims 1 to 6, wherein the TNFRSF agonist or a functional fragment thereof is a polypeptide or a functional fragment thereof, an antibody or a functional fragment thereof, or an antigen-binding fragment thereof.

8. The use according to any one of claims 1 to 7, wherein the TNFRSF agonist or a functional fragment thereof is provided as a fusion protein comprising said TNFRSF agonist or a functional fragment thereof.

9. The use according to any one of claims 1 to 8, wherein the IFN agent or a functional fragment thereof is selected from the group consisting of a Type I IFN agent, a Type II IFN agent and a Type III IFN agent, or functional fragments thereof.

10. The use according to any one of claims 1 to 9, wherein the IFN agent or a functional fragment thereof is IFNα, IFNβ, IFNγ or IFNλ, or functional fragments thereof.

11. The use according to any one of claims 1 to 10, wherein the IFN agent or a functional fragment thereof is IFNβ or IFNγ, or functional fragments thereof.

12. The use according to any one of claims 1 to 11, wherein the IFN agent or a functional fragment thereof is IFNβ, or a functional fragment thereof.

13. The use according to any one of claims 1 to 10, wherein the IFN agent or a functional fragment thereof is IFNα, or a functional fragment thereof.

14. The use according to any one of claims 1 to 13, wherein the IFN agent or a functional fragment thereof is provided as a fusion protein comprising said IFN agent or a functional fragment thereof.

15. The use according to any one of claims 1 to 14, wherein the TNFRSF agonist or a functional fragment thereof and the IFN agent or a functional fragment thereof are provided as a bifunctional immunostimulatory fusion protein comprising the said TNFRSF agonist or a functional fragment thereof, the said IFN agent or a functional fragment thereof and a linker.

16. The use according to any one of claims 1 to 15, wherein the TNFRSF agonist or a functional fragment thereof and the IFN agent or a functional fragment thereof are comprised in a single pharmaceutical composition.

17. The use according to any one of claims 1 to 14, wherein the TNFRSF agonist or a functional fragment thereof and the IFN agent or a functional fragment thereof are comprised in distinct pharmaceutical compositions.

18. A pharmaceutical composition comprising:

a TNFRSF agonist or a functional fragment thereof; and

a Type II IFN agent, a functional fragment of a Type II IFN agent, a Type III IFN agent, or a functional fragment of a Type III IFN agent.

19. A combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof and an interferon (IFN) agent or a functional fragment thereof, for use for treating a HBV infection.